OT Staff Reports

Children’s Hospital of Philadelphia and Stanford University School of Medicine will lead the $5.4 million study ,with patient recruitment beginning in late 2021 or early 2022.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Tunde Peto, MD, offers advice on how to create the best virtual environment for patients diagnosed with diabetic eye disease.

Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Despite varied results, the company will submit a New Drug Application for pegcetacoplan for geographic atrophy to the FDA early next year.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.

Ramin Tadayoni, MD, PhD, discusses the pathology of myopia around the globe.

Horizon Therapeutics announced Tuesday the enrollment of the first patient in its Phase 4 clinical trial analyzing TEPEZZA® for the treatment of thyroid eye disease.

OD-OS’s teleguidance offering addresses the lack of experts and also benefits teaching in retina laser care.

The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

According to the Academy and RPB, the grant recipients will use the IRIS Registry database to improve the diagnosis and treatment of eye disease.

Led by eye care nonprofit Orbis with support from Alcon, the training will build eye care professionals' skills to treat retinopathy of prematurity in Latin America

According to McKinsey’s Hospital Insights Survey, hospital outpatient and procedural volumes were nearly 4 percent higher in July compared to 2019, but ophthalmology was down during the same period.

Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.

According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.

The approval could lead hospitals, universities, corporations and even local governents to enact vaccination mandates.

RightEye Sensorimotor is a new technology designed to greatly improve patient care and increase optometry and ophthalmology practice revenue.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.

Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.

Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.

The company shared data from its two-year Phase III KITE trial and the one-year phase III KINGFISHER trial.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

pVerify's Vision Benefits API allows front-office staff to handle vision eligibility verifications seamlessly in their own EHR.

Heru Inc., announced Thursday that it has partnered with Vision Source on the commercial availability launch of re:Vive, a wearable diagnostics and visual field application.